Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab vs Docetaxel in NSCLC (OAK)
NCT02008227Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2014
- Primary completion
- Jul 2016
- Modality
- Monoclonal Antibodies
- Countries
- 31
01
Overview
A Phase 3 trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Mar 2014; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02008227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02008227.